View Older Stories

Jul 23, 2026 04:06PM Summit Therapeutics posts Q2 loss, reports ivonescimab trial data

Jul 23, 2026 07:10AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Jul 22, 2026 04:30PM Arcus and Summit team up to test kidney cancer drug combo

Jul 22, 2026 06:30AM Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial

Jul 16, 2026 06:48AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Jul 15, 2026 07:37AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Jun 22, 2026 09:26AM Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group

Jun 12, 2026 12:37PM Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares

Jun 3, 2026 06:51AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald

Jun 1, 2026 08:23AM Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)

Jun 1, 2026 07:55AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald

Jun 1, 2026 07:41AM Summit Therapeutics (SMMT) Reiterated at Buy by Stifel on HARMONi-6 'Win'

Jun 1, 2026 02:53AM Summit's ivonescimab shows survival benefit in lung cancer trial

May 26, 2026 09:14AM Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)

May 22, 2026 07:28AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald

May 22, 2026 06:35AM H.C. Wainwright Downgrades Summit Therapeutics plc (SMMT) to Neutral

May 22, 2026 05:02AM Citi Opens Cat Call on Summit Therapeutics plc (SMMT)

May 21, 2026 04:37PM Bernstein SocGen Group Starts Summit Therapeutics plc (SMMT) at Underperform

May 4, 2026 07:32AM Summit Therapeutics plc (SMMT) PT Lowered to $23 at H.C. Wainwright

Apr 30, 2026 04:56PM Summit Therapeutics (SMMT) Tops Q1 EPS by 4c

Apr 21, 2026 12:33PM Stifel on Summit Therapeutics plc (SMMT): 'first look, ever, at an emerging OS from an invonescimab P3 randomized against antiPD-1 (tislelizumab)'

Apr 17, 2026 09:58AM UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Apr 16, 2026 03:26PM Summit Therapeutics (SMMT) spreader of 2K contracts of June 25 and 30 calls, share price up 13.6%

Apr 7, 2026 04:27PM Stifel Starts Summit Therapeutics plc (SMMT) at Buy, $45 PT

Apr 6, 2026 07:40AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald

Mar 27, 2026 08:16AM Summit Therapeutics to present ivonescimab data at ELCC 2026

Mar 23, 2026 04:53AM Summit Therapeutics (SMMT) Added to Citi 90-Day Upside Catalyst Call List

Mar 16, 2026 12:50AM Jefferies Downgrades Summit Therapeutics plc (SMMT) to Hold

Feb 25, 2026 06:38AM Summit Therapeutics plc (SMMT) PT Lowered to $30 at H.C. Wainwright

Feb 24, 2026 05:15AM Citi Opens Catalyst Watch on Summit Therapeutics plc (SMMT)

Feb 24, 2026 04:31AM Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens

Feb 23, 2026 04:22PM Summit Therapeutics (SMMT) Misses Q4 EPS by 21c

Feb 2, 2026 06:50AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Jan 30, 2026 05:41AM Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens

Jan 29, 2026 07:30AM FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab

Jan 14, 2026 06:54AM H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Jan 13, 2026 04:21AM Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens

Jan 12, 2026 06:15AM Summit Therapeutics partners with GSK for cancer drug combination trial

Jan 12, 2026 06:01AM Summit Therapeutics files FDA application for cancer drug ivonescimab

Dec 19, 2025 06:56AM Summit Therapeutics' (SMMT) HARMONi-2 Important 2026 Catalyst - Cantor Fitzgerald

Dec 17, 2025 04:02AM Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight

Nov 7, 2025 09:02AM Ivonescimab shows survival benefit in lung cancer study

Oct 31, 2025 07:00AM Summit to present ivonescimab lung cancer trial results at SITC 2025

Oct 30, 2025 04:32AM Summit Therapeutics (SMMT) files for 26.68M share offering by selling stockholders

Oct 21, 2025 06:43AM Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright

Oct 20, 2025 02:17PM Summit Therapeutics plc (SMMT) PT Lowered to $42 at Jefferies

Oct 20, 2025 09:50AM Citizens Highlights Summit’s (SMMT) Ivonescimab Superiority, Reiterates at Outperform

Oct 20, 2025 09:22AM UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Oct 20, 2025 07:37AM Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT) After Management Meet

Oct 20, 2025 06:48AM Summit Therapeutics (SMMT) Tops Q3 EPS by 4c

View Older Stories